VTVT vTv Therapeutics Inc.

1.96
+0.04  (+2%)
Previous Close 1.92
Open 1.91
Price To Book -2.72
Market Cap 132,814,976
Shares 67,762,743
Volume 138,411
Short Ratio
Av. Daily Volume 897,257
Stock charts supplied by TradingView

NewsSee all news

  1. vTv Therapeutics Announces 2019 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

    HIGH POINT, N.C., Feb. 20, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT) today reported financial results for the fourth quarter and year ended December 31, 2019, and provided an update on recent

  2. vTv Therapeutics Announces Positive Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes

    - TTP399, a novel glucokinase activator, achieves primary objective of a statistically significant reduction in HbA1c, without increases in hypoglycemia or ketoacidosis - Company to host investor conference call today

  3. vTv Therapeutics to Host Investor Call and Announce Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 – Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes

    HIGH POINT, N.C., Feb. 07, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT) today announced that it will release the topline results from Part 2 of the Phase 2 Simplici-T1 trial assessing TTP399 as an oral

  4. vTv Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

    HIGH POINT, N.C., Dec. 02, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and

  5. vTv Therapeutics Announces 2019 Third Quarter Financial Results and Update

    SimpliciT-1 Study of TTP399 in patients with type 1 diabetes fully-enrolled Elevage Study of azeliragon in patients with mild Alzheimer's disease with type 2 diabetes actively enrolling HIGH POINT, N.C., Oct. 30, 2019

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 Part 2 data met primary endpoint - February 10, 2020.
TTP399
Type 1 Diabetes
Phase 2 data released August 2016. Primary endpoint met.
TTP399 - AGATA
Type 2 Diabetes
Phase 2 primary endpoint met - December 14, 2016.
TTP273 - LOGRA
Type 2 Diabetes
Phase 3 data both Part A (April 9, 2018) and Part B (June 12, 2018) did not meet endpoints.
Azeliragon - STEADFAST
Mild Alzheimer’s disease
Phase 2/3 top-line data due late 1H 2021.
Azeliragon
Mild Alzheimer’s disease with type 2 diabetes

Latest News

  1. vTv Therapeutics Announces 2019 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

    HIGH POINT, N.C., Feb. 20, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT) today reported financial results for the fourth quarter and year ended December 31, 2019, and provided an update on recent

  2. vTv Therapeutics Announces Positive Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes

    - TTP399, a novel glucokinase activator, achieves primary objective of a statistically significant reduction in HbA1c, without increases in hypoglycemia or ketoacidosis - Company to host investor conference call today

  3. vTv Therapeutics to Host Investor Call and Announce Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 – Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes

    HIGH POINT, N.C., Feb. 07, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT) today announced that it will release the topline results from Part 2 of the Phase 2 Simplici-T1 trial assessing TTP399 as an oral

  4. vTv Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

    HIGH POINT, N.C., Dec. 02, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and

  5. vTv Therapeutics Announces 2019 Third Quarter Financial Results and Update

    SimpliciT-1 Study of TTP399 in patients with type 1 diabetes fully-enrolled Elevage Study of azeliragon in patients with mild Alzheimer's disease with type 2 diabetes actively enrolling HIGH POINT, N.C., Oct. 30, 2019

  6. vTv to Host Key Opinion Leader Event to Discuss the Type 1 Diabetes Treatment Landscape and Emerging Therapies as Adjuncts to Insulin

    HIGH POINT, N.C., Oct. 03, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), today announced that the Company will host a key opinion leader (KOL) presentation and webcast discussing the type 1 diabetes

  7. vTv Therapeutics Presents Additional Positive Data from the Phase 2 Simplici-T1 Study in Patients with Type 1 Diabetes at 55th Annual Meeting of the European Association for the Study of Diabetes

    HIGH POINT, N.C., Sept. 18, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), today presented additional positive data from its phase 2 Simplici-T1 study in patients with type 1 diabetes (T1D) at the 55th

  8. vTv Therapeutics to Present Posters at Two Scientific Conferences in September

     Presenting New Clinical Data from Phase 2 Study in Type 1 Diabetes with Liver Selective GKA Program Pre-Clinical Data in NASH with the NRF2/Bach1 Program  HIGH POINT, N.C., Sept. 11, 2019 (GLOBE NEWSWIRE) -- vTv

  9. vTv Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    HIGH POINT, N.C., Sept. 04, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes and